- Investigator
- Ginger Clark
- Status
- Accepting Candidates
About me
My name is Virgina Clark, MD, and I am an associate professor of medicine and the program director of the gastroenterology fellowship in the division of gastroenterology, hepatology & nutrition. My clinical practice is focused on liver disease with specialization in genetic and metabolic liver diseases. I am a diplomate of the American Board of Internal Medicine with Board Certification in internal medicine, gastroenterology and transplant hepatology.
I earned my medical degree at Emory University in Atlanta, followed by completing an internal medicine residency at Vanderbilt University in Nashville. I arrived at the University of Florida in 2004 to begin a gastroenterology fellowship and then completed an additional year of advanced training in liver transplantation. Following my postgraduate training, I earned a master of science degree in clinical investigation at the UF and accepted a faculty position within the division. Since then, I’ve been the recipient of numerous Exemplary Teacher Awards from the UF College of Medicine.
I remain engaged in practice as a member of the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), the American College of Gastroenterology (ACG) and the Alpha-1 Foundation. Currently, I am the principle investigator (PI) on eight industry-sponsored studies and co-investigator on an NIH-NIDDK funded study. My areas of research specialization include participation in investigator-initiated research and multicenter clinical trials which assess medical and experimental alternatives for Alpha-1 antitrypsin deficiency, fatty liver disease, primary biliary cirrhosis and primary sclerosing cholangitis and hepatitis C. I am the author of 30 peer-reviewed publications and seven non-peer reviewed publications.
My Locations
Active clinical trials
The main aim of this study is to learn if fazirsiran is safe during long-term use in people with liver disease caused by the abnormal Z-alpha-1 antitrypsin (Z-AAT) protein. People who have taken part in previous fazirsiran studies (AROAAT2001�
- Investigator
- Ginger Clark
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
The main aim of this study is to learn if fazirsiran reduces liver scarring (fibrosis) compared to placebo. Other aims are to learn if fazirsiran slows down the disease worsening in the liver, to get information on how fazirsiran affects the body�
- Investigator
- Ginger Clark
- Status
- Accepting Candidates
- Ages
- 18 Years - 75 Years
- Sexes
- All
My research
Top areas of exploration
- Liver Cirrhosis , 8 publications
- Hepatitis C , 8 publications
- alpha 1-Antitrypsin Deficiency , 6 publications
- Antiviral Agents , 6 publications
Research activity
Accepted insurances
Please note: Some physicians and practices might not accept a specific insurance plan. Our list is also subject to change, and sometimes that change is not yet reflected in this list. Please contact the practice to confirm that your insurance is accepted. A representative will be happy to assist you.
See all insurancesStories and news
How Carly Spoto Turned a Heartbreaking Diagnosis Into a Lifesaving Journey of Dedication
Carly Spoto, financial specialist at BOBÌåÓý Family Medicine â€� Old Town, had a mother who was presumably a healthy mom of six when her life was unexpectedlyâ€�
